ReviewEuropean respiratory review : an official journal of the European Respiratory Society2011
Lymphangioleiomyomatosis: what do we know and what are we looking for?
Review in European respiratory review : an official journal of the European Respiratory Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Hepatic perivascular epithelioid cell tumor (PEComa): Clinicopathological Findings and Prognosis-A Systematic Review and Meta-Analysis.Iranian journal of pathology · 2026Review
- The importance of mechanical forces in chronic respiratory diseases.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Multidisciplinary Management of Lymphangioleiomyomatosis Presenting With Severe Bilateral Pneumothorax During Pregnancy: A Case Report.Case reports in pulmonology · 2026Article
- Targeting fibroblast-endothelial cell interactions in LAM pathogenesis using 3D spheroid models and spatial transcriptomics.JCI insight · 2025Article
- FGFR4 p.Gly388Arg polymorphism in PBMCs of LAM patients: findings of a pilot study.Frontiers in medicine · 2025Article
- Targeting Fibroblast-Endothelial Interactions in LAM Pathogenesis: 3D Spheroid and Spatial Transcriptomic Insights for Therapeutic Innovation.bioRxiv : the preprint server for biology · 2024Article
- Article
- Hyperactive mTORC1 in lung mesenchyme induces endothelial cell dysfunction and pulmonary vascular remodeling.The Journal of clinical investigation · 2023Article
- Lymphangioleiomyomatosis With Atypical Presentation Following Pneumothorax: A Case Report.Cureus · 2023Article
- Phenotypic Features of Cystic Lung Disease in Proteus Syndrome: A Clinical Trial.Annals of the American Thoracic Society · 2022Article
- Bioinformatics analysis of inflammation and oncology in pulmonary lymphangioleiomyomatosis.Medicine · 2022Article
- Long-term clinical course and outcomes in patients with lymphangioleiomyomatosis.Respiratory research · 2022Article
- Missed tuberous sclerosis complex with multi-system complications in a single patient.Radiology case reports · 2022Article
- Sex and gender in interstitial lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2021Article
- Tuberous sclerosis complex-lymphangioleiomyomatosis involving several visceral organs: A case report.World journal of clinical cases · 2021Article
- A 34-Year-Old Woman from Brazil with Pulmonary Lymphangioleiomyomatosis Diagnosed by Raised Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels and Lung Cysts on Computed Tomography Imaging Presenting with COVID-19 Pneumonia.The American journal of case reports · 2021Article
- Article
- Ultra-rare cystic disease.European respiratory review : an official journal of the European Respiratory Society · 2020Article
- Quantitative analysis of computed tomography of the lungs in patients with lymphangioleiomyomatosis treated with sirolimus.Heliyon · 2020Article
- Postpartum Bilateral Tension Pneumothoraces.Cureus · 2019Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
Lymphangioleiomyomatosis (LAM) is a rare disease characterised by proliferation of abnormal smooth muscle-like cells (LAM cells) leading to progressive cystic destruction of the lung, lymphatic abnormalities and abdominal tumours. It affects predominantly females and can occur sporadically or in patients with tuberous sclerosis complex. This review describes the recent progress in our understanding of the molecular pathogenesis of the disease and LAM cell biology. It also summarises current therapeutic approaches and the most promising areas of research for future therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.